Ixion is a Florida-based, early stage biotechnology company that is developing therapies focused on somatic cellular therapies to treat diabetes, based on selecting, proliferating, and directing the differentiation of adult pancreatic stem cells into insulin-producing islet preparations for transplantation.
Stem Cell / Diabetes. We are focused on the development of human somatic cellular therapies to treat diabetes, based on selecting, proliferating, and directing the differentiation of adult pancreatic stem cells into insulin-producing islet preparations ("preps").
Our goal is to produce commercial quantities of these preps and be the first company in the world to treat diabetes by implanting adult stem cell-derived islet preparations into patients. We expect to make use of the well-established Edmonton Protocol, a procedure that has become the "gold standard" for islet transplantation for diabetes.
In this area our initial product shall consist of allogeneic, cultured, functional islet preparations, derived in vitro from adult, pancreatic duct stem cells, which we call human Islet-Producing Stem Cells ("hIPSCs")-derived islets. We have established proof of principle that islet preps derived from IPSCs can reverse diabetes (published in the March 2000 issue of Nature Medicine) We have successfully established hIPSC cell lines from human pancreatic tissue, and are implanting mice to establish viability and expansion potential. We will follow with pre-clinical toxicology studies in two species. Although there are many possible sources of tissue for the cellular treatment of diabetes, we believe that adult pancreatic duct stem cells present the shortest and least complicated path to the objective.
Weaver H. Gaines, Chairman of the Board and Co-Founder
Ixion Biotechnology, Inc.
13709 Progress Blvd, Box 13, Suite N-109
Alachua, Florida 32615
E-mail us at info@ixion-biotech.com
Voice: 386-462-2279 Fax: 386-462-2326
